Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Nektar TherapeuticsNASDAQ: NKTR

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$110.31M, compared with $4.09M a year earlier. Trailing-twelve-month net change in cash was $15.21M.

Context

  • Net change in cash amounted to 52.8% of revenue in FY2025, up 43.6 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near -$110.31M or moves back toward the trailing-twelve-month quarterly average of $3.8M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$110.31M-185.7% QoQ
Last fiscal yearDec 2025
-$29.14M-424.6% YoY
LTMJun 2026
$15.21M+1.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2794.5%——
1 year-424.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(29.14M) USD
Year-over-year change
-424.6%

Net Change in Cash vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.2% is the 4th highest of 9, against a peer median of -75.2%.
  • Net change in cash amounts to 27.9% of revenue for NKTR, versus a peer median of 83.8%.
NKTR Competitors
Net Change in Cash for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$98M USD-206.5%+7.5%83.8%
MGNXMacroGenics, Inc.LTM Mar 2026$79.05M USD-221.2%+105.0%50.3%
CGENCompugen Ltd.LTM Dec 2025$72.37M USD—+192.0%99.5%
IMTXImmatics N.V.LTM Mar 2026€51.59M EUR-57.3%+106.7%138.3%
ANLAdlai Nortye Ltd.LTM Jun 2024$37.95M USD—+20.2%584.8%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$35.1M USD+1528.7%-56.4%—
CHRSCoherus Oncology, Inc.LTM Mar 2026$32.8M USD+118.5%-52.8%70.0%
IPHAInnate Pharma S.A.FY2025€30.44M EUR+623.1%+15.9%1092.1%
IMCRImmunocore Holdings plcLTM Mar 2026$24.17M USD-93.2%-52.2%6.3%
NKTRNektar TherapeuticsLTM Jun 2026$15.21M USD+1.2%—27.9%
XNCRXencor, Inc.LTM Jun 2026$126K USD-99.1%—0.1%
Peer median (excluding NKTR) —-75.2%+15.9%83.8%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.